Will giving coffee to babies keep them awake as adults?

Oct 08, 2009

An F1000 evaluation looks at a Canadian study on how giving caffeine to newborn rats has a long-lasting and detrimental effect on sleep and breathing in adulthood.

Breathing problems are the leading causes of hospitalisation and death in premature babies. These babies are therefore often given because of its qualities as a respiratory stimulant. Until recently, the long-term effects of this treatment in humans have not been examined.

However, Gaspard Montandon and colleagues showed in the Journal of Physiology that the use of caffeine in neonates can cause serious alterations in the sleeping patterns of adult rats as a result of its effect on the developing . abnormality is a significant indicator for ill health and reduced life span.

When the caffeine-treated rats reached adulthood, their sleeping time was reduced, the length of time they took to reach the first stage of sleep was increased, and their non-REM sleep was fragmented. at rest was higher than in rats not treated with caffeine.

In his review of the study, F1000 Faculty Member James Duffin of the University of Toronto says the results "raise concerns about the long-term consequences of neonatal caffeine administration on brain development and behaviour."

More information: An abstract of the original paper by Montandon et al. (Caffeine in the neonatal period induces long-lasting changes in sleep and breathing in adult ) is at http://jp.physoc.org/content/early/2009/09/18/jphysiol.2009.171918

Source: Faculty of 1000: Biology and Medicine

Explore further: Amgen misses 1Q views as higher costs cut profit

add to favorites email to friend print save as pdf

Related Stories

Caffeine powder is recalled

May 21, 2007

The U.S. Food and Drug Administration said Spectrum Laboratory Products Inc. is recalling its Caffeine Citrated Powder due to potential potency issues.

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

Genetic code of the deadly tsetse fly unraveled

Mining the genome of the disease-transmitting tsetse fly, researchers have revealed the genetic adaptions that allow it to have such unique biology and transmit disease to both humans and animals.

Ocean microbes display remarkable genetic diversity

The smallest, most abundant marine microbe, Prochlorococcus, is a photosynthetic bacteria species essential to the marine ecosystem. An estimated billion billion billion of the single-cell creatures live i ...